Molecular characteristics of oxazolidinone resistance in enterococci from a multicenter study in China

Abstract

Background

Linezolid-resistant enterococci pose great challenges in clinical practice. The aim of this study is to study the mechanisms underlying the resistance and genetic environment of antimicrobial resistance gene of linezolid-resistant enterococci.

Results

The linezolid MICs of 16 enterococci were 4 mg/L to 16 mg/L. Four strains belonged to multi-drug resistant (MDR) bacteria. The sequence types (STs) of 13 enterococci strains performed WGS were diverse: 3 ST476, 1 ST86, ST116, ST480, ST59, ST416, ST21, ST67, ST16, ST585 and ST18. None of them carried multi-drug resistance gene cfr. Only one strain had the G2658 T mutation of target 23S rRNA gene. Thirteen (13/16, 81.3%) strains harbored the novel oxazolidinone resistance gene optrA. WGS analysis showed that the optrA gene was flanked by sequence IS1216E insertion in 13 strains, and optrA was adjacent to transposons Tn558 in two strains and Tn554 in one strain. The optrA gene was identified to be co-localized with fexA, the resistance genes mediated florfenicol resistance in 13 strains, and ermA1, the resistance genes mediated erythromycin resistance in 9 strains, indicating that linezolid-resistant strains may be selected due to non-oxazolidinone antibiotics (i.e. macrolides and florfenicol) usage.

Conclusion

Our findings demonstrate the high diversity of optrA-carrying genetic platforms. The mobile genetic elements (MGEs) may play an important role in the dissemination of optrA into the enterococci isolates of human origin. The genetic evidence of transferable feature and co-selection of optrA should be gave more attention in clinical practice.

Background

Linezolid, which belongs to oxazolidinone, is the clinically last resort to treat vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), and other multi-drug Gram-positive bacteria [1]. Linezolid exerts antibacterial effects by inhibiting the binding of mRNA to the ribosome, thereby affecting the synthesis of the protein [1]. It is generally considered that linezolid is a completely synthetic antibiotic, and theoretically, there should be no natural resistance phenomenon. Unfortunately, clinically resistant strains have emerged shortly after use of linezolid in clinical practice [2, 3]. The occurrence of linezolid-resistant strains show an increasing trend, especially in animal husbandry [4], which should attract sufficient attention.

The resistance to linezolid by gram-positive bacteria can be achieved by target-modified 23S rRNA mutations [5], acquiring exogenous chloramphenicol-florfenicol resistance (cfr) [6], optrA [7] or poxtA [8]. Targets 23S rRNA, L3, L4 and L22 mutations usually affect ribosome function and easily reverse in the absence of selective pressure. Therefore, chemical modifications (such as methylation) of rRNA are the more common resistance mechanisms of linezolid. The cfr gene encodes a methyltransferase that modifies the 23S rRNA at position A2503, which confers resistance to phenicols, lincosamide, oxazolidinones, pleuromutilin, and streptogramin A (PhLOPS_A phenotype) [9]. The cfr gene has been identified in a variety of genera, including Staphylococcus [10], Bacillus [11], Enterococcus [12], Macrococcus [13], Jeotgalicoccus [13], Streptococcus [14], Proteus [15] and Escherichia [16]. The cfr gene widely disseminates among oxazolidinone-resistant isolates from human [17] and animal [18] origin, which represents a serious threat to public health. Recently, two cfr variants, cfr(B) and cfr(C), have been found in Enterococcus faecium [19], Clostridium difficile [20] and Campylobacter [21]. The cfr gene was often found on a number of different plasmids [7, 15, 22], and integrated into transposons, leading to dissemination of this gene among the same or between different species of bacteria.

The transferable gene, optrA, has been identified, which confers cross-resistance to phenicols and oxazolidinones, including tedizolid [23]. This gene was identified in enterococci and staphylococci from clinical [24], healthy human and animal isolates [25, 26]. The resistance gene optrA can be located either on plasmid or chromosome [26]. Recently, one florfenicol-resistant Staphylococcus sciuri isolate, which carried both optrA and cfr, was identified in pig [27]. In this study, we investigated the oxazolidinones resistance genes among linezolid-resistant isolates in Chinese hospitals and utilized whole-genome sequencing (WGS), and further analyzed the genetic environment surrounding the resistance genes.

Materials and methods

Bacterial strains

A total of 15 non-duplicable linezolid-resistant enterococci strains and one linezolid intermediate-resistant enterococci strain (13 E. faecalis and 3 E. faecium) (1.5%, 16/1067) were collected from specimens of 16 patients from 9 hospitals between 2009 and 2013 in 6 provinces of China, including 5 samples from Beijing, 4 samples from Guangdong, 3 samples from Zhejiang, 2 samples from Fujian, 1 sample from Jiangsu and 1 sample from Hubei (Table 1.). Among the 16 strains, 6 were recovered from patients with urinary tract infection, 5 from patients with bacteremia, 4 from patients with wound infection and 1 from patients with biliary tract infection. Among the 16 strains, 7 strains (1203_10W003, 1202_13E004, 1202_21W014, 19113, 19677, 19506 and SZ21494) were isolated in our previous study [28], and the 9 remaining strains were isolated in this study. Bacteria were first identified at the species level using the VITEK system (bioMerieux, Crapome, France), followed by a molecular method based on the 16S rRNA gene, and then by sequencing analysis.

Table 1.

Clinical, phenotypic and genotypic data for the linezolid-resistant Enterococci isolates investigated

Isolate no.	Organism	Isolation year	Hospitalb	Isolation site	STc	MICs (mg/L)a											Linezolid resistance genes	23S rRNA gene mutations	Other resistance genes
						LNZ	P	AMP	VAN	TEC	DAP	TGC	LVX	ERY	HLG	Antibiotic resistance profiles
29462	E. faecalis	2009	ZRYH	urine	86	8	4	<=2	2	<=0.125	0.5	0.06	8	> 4	R	LVX, ERY	optrA	–	emeA, ANT(6)-Ia, AAC(6′)-Ie-APH(2″)-Ia, dfrG, dfrE, lsaA, fexA, cat, efrB, efrA, ermB, tetM, tet(L)
ZJ11066	E. faecalis	2011	ZJFY	blood	116	8	2	<=2	1	0.125	0.5	0.12	8	> 4	R	LVX, ERY	optrA	–	emeA, APH(3′)-IIIa, AAC(6′)-Ie-APH(2″)-Ia, dfrF, dfrG, dfrE, lnuG, lsaA, fexA, efrA, efrB, ermB, ermA1, tet(L), tetM
JS11041	E. faecium	2011	JSRM	urine	ND	8	> = 64	> = 32	0.5	0.25	2	0.06	8	> 4	R	P, AMP, LVX, ERY	–	–	ND
19113	E. faecalis	2011	SZRM	bile	ND	8	> = 64	> = 32	2	<=0.125	0.5	0.06	1	> 4	R	P, AMP, LVX, ERY	–	–	ND
ZJLRE1	E. faecium	2011	ZJFE	blood	ND	16	> = 64	> = 32	1	0.5	1	0.06	8	> 4	R	P, AMP, LVX, ERY	–	G2658 T	ND
1207_26W003	E. faecalis	2012	BJRM	urine	476	4	2	<=2	1	0.12	0.5	0.06	8	> 4	R	LVX, ERY	optrA	–	emeA, APH(3′)-IIIa, AAC(6′)-Ie-APH(2″)-Ia, aad(6), ANT(9)-Ia, dfrG, dfrE, lnuB, lsaE, lsaA, mdtF, SAT-4, cat, fexA, efrB, efrA, ermA1, ermB, tet(L), tetM
1203_10W003	E. faecalis	2012	BJRM	urine	480	8	2	<=2	1	0.12	0.5	0.06	8	> 4	R	LVX, ERY	optrA	–	emeA, AAC(6′)-Ie-APH(2″)-Ia, APH(3′)-IIIa, aad(6), ANT(6)-Ia, dfrG, dfrE, lnuB, lsaE, lsaA, SAT-4, cat, fexA, efrA, efrB, ermB, ermA1, tetM, tet(L)
19677	E. faecalis	2012	SZRM	blood	59	8	2	<=2	0.5	0.12	0.5	0.12	0.03	> 4	R	ERY	optrA	–	emeA, dfrE, lsaA, fexA, efrA, efrB, ermA1, tetM, tet(L)
19506	E. faecium	2012	SZRM	wound	18	16	> = 64	> = 32	0.5	0.25	2	0.06	8	> 4	S	P, AMP, LVX, ERY	optrA	–	AAC(6′)-Ii, dfrG, efmA, msrC, fexA, ermA1
1202_13E004	E. faecalis	2012	BJRM	wound	416	16	8	<=2	2	<=0.125	0.5	0.12	8	> 4	R	LVX, ERY	optrA	–	emeA, ANT(6)-Ia, AAC(6′)-Ie-APH(2″)-Ia, dfrG, dfrE, lsaA, fexA, efrB, efrA, ermB, ermA1, tet(L), tetM
1202_21W014	E. faecalis	2012	BJRM	urine	21	8	4	<=2	2	<=0.125	0.5	0.12	8	> 4	R	LVX, ERY	optrA	–	emeA, AAC(6′)-Ie-APH(2″)-Ia, aad(6), ANT(6)-Ia, dfrG, dfrE, lnuG, lsaA, SAT-4, fexA, cat, efrA, efrB, ermB, tet(L)
SZ21494	E. faecalis	2012	SZRM	wound	67	8	4	<=2	1	<=0.125	1	0.06	1	> 4	S	ERY	optrA	–	emeA, dfrE, dfrG, lnuG, lsaA, fexA, cat, efrA, efrB, ermB, ermA1, tetM, tet(L)
XM2013_71028	E. faecalis	2013	XMDY	wound	16	8	2	<=2	1	<=0.125	1	0.06	0.5	> 4	R	ERY	optrA	–	emeA, APH(3′)-IIIa, AAC(6′)-Ie-APH(2″)-Ia, ANT(9)-Ia, aad(6), dfrG, dfrE, lnuB, lsaE, lsaA, SAT-4, fexA, cat, efrB, efrA, ermB, ermA1, tetM
XM2013_42321	E. faecalis	2013	XMDY	urine	585	16	4	<=2	1	<=0.125	0.5	0.06	8	> 4	R	LVX, ERY	optrA	–	emeA, APH(3′)-IIIa, AAC(6′)-Ie-APH(2″)-Ia, aad(6), ANT(9)-Ia, dfrE, dfrG, lmrD, lnuB, lsaE, lsaA, SAT-4, cat, fexA, efrB, efrA, ermB, tetM, tet(L)
TZ2	E. faecalis	2013	TZSY	blood	476	8	2	<=2	1	<=0.125	0.5	0.12	8	> 4	R	LVX, ERY	optrA	–	emeA, AAC(6′)-Ie-APH(2″)-Ia, APH(3′)-IIIa, aad(6), ANT(6)-Ia, dfrG, dfrE, lsaA, SAT-4, fexA, cat, efrB, efrA, ermA1, ermB, tet(L), tetM
WHXH	E. faecalis	2013	WHDS	blood	476	8	4	<=2	2	<=0.125	0.5	0.12	8	> 4	S	LVX, ERY	optrA	–	emeA, AAC(6′)-Ie-APH(2″)-Ia, APH(3′)-IIIa, aad(6), ANT(9)-Ia, dfrE, dfrG, lnuB, lsaE, lsaA, SAT-4, cat, fexA, efrB, efrA, ermB, tetM, tet(C), tet(L)

^aMICs, the minimal inhibitory concentrations; LNZ, linezolid, susceptible (S): ≤ 2 mg/L, intermediate (I): 4 mg/L, resistant (R): ≥ 8 mg/L; P, penicillin, S: ≤ 2 mg/L, R: ≥ 8 mg/L; AMP, ampicillin, S: ≤ 2 mg/L, R: ≥ 8 mg/L; VAN, vancomycin, S: ≤ 4 mg/L, I: 8–16 mg/L, R: ≥ 32 mg/L; TEC, teicoplanin, S: ≤ 8 mg/L, I: 16 mg/L, R: ≥ 32 mg/L; DAP, S: ≤ 1 mg/L, susceptible-dose dependent (SDD): 2–4 mg/L, R: ≥ 8 mg/L; TGC, tigecycline, no breakpoint in CLSI M100; LVX, levofloxacin, S: ≤ 2 mg/L, I: 4 mg/L, R: ≥ 8 mg/L; ERY, erythromycin, S: ≤ 0.5 mg/L, I: 1–4 mg/L, R: ≥ 8 mg/L; HLG, high-level gentamycin (500 mg/L); −, negative; ND, not determined

^bZRYH, China-Japan Friendship Hospital; ZJFY, 1st Affiliated Hospital of Zhejiang University; JSRM, Jiangsu Province Hospital; SZRM, Shenzhen People’s Hospital; ZJFE, 2nd Affiliated Hospital of Zhejiang University; BJRM, Peking University People’s Hospital; XMDY, 1st Affiliated Hospital of Xiamen University; TZSY, Taizhou Hospital of Zhejiang Province; WHDS, Wuhan Fourth Hospital

^cST sequence type, ND not determined

Antimicrobial susceptibility testing

The minimal inhibitory concentrations (MICs) of 8 antimicrobial agents were determined by the agar dilution method, and tigecycline and daptomycin by broth microdilution. The antimicrobial agents tested included linezolid (Sigma Chemical Co., St. Louis, MO, USA), vancomycin (Sigma), teicoplanin (Sigma), levofloxacin (Sigma), erythromycin (Sigma), tigecycline (Pfizer, NY, USA), daptomycin (Cubist Pharmaceuticals, MA, USA), penicillin (Sigma), ampicillin (Sigma) and gentamycin (Sigma). E. faecalis ATCC 29212 was used for quality control in antimicrobial susceptibility testing. The results of susceptibility testing were interpreted according to CLSI guideline M100-S27. Isolates resistant to three or more antibiotics of different families were considered to be multi-drug resistant (MDR).

Molecular detection of resistance genes and mutations

The resistance genes cfr and optrA were determined by PCR as described previously. The mutation of domain V of the 23S rRNA gene was determined by PCR combined with sequencing as described previously [29]. Nucleotide sequences were compared with the linezolid-susceptible E. faecalis and E. faecium from Peking University People’s Hospital during the same period. The mutation was identified by the E. coli numbering.

Whole-genome sequencing (WGS)

Total genomic DNA of 13 enterococci strains carrying optrA gene was extracted by the standard phenol/chloroform method. The whole-genome sequencing was performed using Illumina technology. The sequences with read length of 150 bases were assembled into contigs using SPAdes (v.3.9.0) [30]. Plasmid content associated with optrA was analyzed using the contigs obtained by plasmidSPAdes. The assembled contigs were annotated by the Prokka v1.12 [31]. Insertion sequences (IS) were identified using ISFinder [32]. Multilocus sequence types (MLST) were assigned using the silico tool hosted by Center for Genomic Epidemiology (CGE) (www.genomicepidemiology.org). The resistance genes were identified by ResFinder 3.0 [33]. Maximum likelihood phylogenetic analysis of the core genome was performed using RAxML (Linux version v7.2.8) [34]. The sequences of the optrA-containing regions of 13 enterococci strains have been deposited at GenBank under the following accession numbers MH225413 (1202_13E004), MH225414 (1202_21W014), MH225415 (1203_10W003), MH225416 (1207_26W003), MH225417 (19506), MH225418 (19677), MH225419 (29462), MH225420 (SZ21494), MH225421 (TZ2), MH225422 (WHXH), MH225423 (XM2013_42321), MH225424 (XM2013_71028) and MH225425 (ZJ11066).

Results

Susceptibility profiles of linezolid-resistant enterococci isolates

The susceptible breakpoint of enterococci to linezolid is defined as less than or equal to 2 mg/L, and the resistant breakpoint is defined as greater than or equal to 8 mg/L. The linezolid MICs of 16 enterococci were 4 mg/L to 16 mg/L, respectively. There were no significant differences in the linezolid MICs between optrA-positive strains (4–16 mg/L) and optrA-negative strains (8–16 mg/L). Most of the optrA-positive strains also exhibited resistance to erythromycin (16/16, 100%), levofloxacin (12/16, 75%) and high-level gentamycin (500 mg/L) (13/16, 81.3%). All strains were susceptible to vancomycin, teicoplanin, daptomycin and tigecycline. Three E.faecium and one E. faecalis strains (4/16, 25%) were resistant to penicillin and ampicillin, and all of 16 enterococci strains didn’t possess beta-lactamase. Four strains (4/16, 25%) belonged to MDR organism (Table 1).

Distribution of antimicrobial resistance genes

None of 16 linezolid-resistant enterococci strains contained cfr gene. Only one strain had the G2658 T mutation in 23S rRNA gene with linezolid MIC of 16 mg/L. Most of the linezolid-resistant enterococci strains (n = 13) carried optrA gene (Table 1).

In addition to optrA genes, all optrA-positive strains harbored phenicols resistance gene fexA (13/13, 100%), erythromycin resistance genes of different erm gene classes (ermA1, ermB) (13/13, 100%), trimethoprim resistant dihydrofolate reductase different dfr gene classes (dfrE, dfrG) (13/13, 100%), ATP-binding cassette (ABC) antibiotic efflux pump different gene classes (lsaA, lsaE, efrA, efrB) (13/13, 100%). Further, majority optrA-positive strains carried tetracycline resistance genes of different tet gene classes (tet[C], tet[L], tetM) (12/13, 92.3%), multidrug and toxic compound extrusion (MATE) transporter emeA gene (12/13, 92.3%) and aminoglycosides inactivating enzyme different gene classes (AAC(6′)-Ii, AAC[6′]-Ie-APH[2″]-Ia, APH[3′]-IIIa, aad [6], ANT[6]-Ia, ANT[9]-Ia) (10/13, 76.9%). Various additional resistance genes were identified including cat, lnuB, lnuG, mdtF, SAT-4 and efmA.

Core-genome phylogenetic analysis

The 12 E. faecalis isolates performed WGS were classified into 10 sequence types (STs): 3 ST476, 1 ST86, ST116, ST480, ST59, ST416, ST21, ST67, ST16 and ST585, respectively. One E. faecium isolate belonged to ST18.

The phylogenetic tree of 12 E. faecalis isolates harboring optrA gene showed that two of these isolates (29462 and XM2013_42321) were genetically unrelated with the rest isolates. Importantly, 1207_26W003 (Beijing), TZ2 (Zhejiang) and WHXH (Hubei) were recovered from different cities, were found very closely related (99.9%), and all of 3 strains belonged to ST476. In addition, strain 19677 recovered from Guangdong was closely related (99.4%) to strain 1202_13E004 recovered from Beijing. Further, strain 1203_10W003 isolated from Beijing and strain XM2013_71028 isolated from Fujian was closely related (99.3%) (Fig. 1).

Fig. 1.

Maximum-likelihood phylogenetic tree of E. faecalis (n = 12)

Genetic environment of optrA on plasmids or chromosome

Thirteen contigs containing the optrA gene were blasted in the GenBank database, and 10 contigs were mapped against the plasmids (pE121 [GenBank accession number KT862776] and pE419 [KT862777]). The size of these 10 contigs was between 6372 bp and 21568 bp. According to the gene arrangements, the 10 contigs were divided into 4 groups: group 1 (29462 [MH225419], 1202_21W014 [MH225414]), group 2 (1203_10W003 [MH225415], SZ21494 [MH225420], ZJ11066 [MH225425]), group 3 (1207_26W003 [MH225416], 19677 [MH225418], XM2013_71028 [MH225424]), group 4 (WHXH [MH225422], XM2013_42321 [MH225423]). The genetic environment of optrA in Group 1 was similar to that of plasmid pE121 (KT862776). Compared to the plasmid pE121, ermA1 gene was absent and the rest of the sequences were almost identical. The genetic environment of optrA from Group 2 to Group 4 resembled that of plasmid pE419 (KT862777). Compared with pE419, the intergenic region between the left IS1216E and the first hypothetical protein was truncated in Group 2, two hypothetical proteins between optrA gene and the right IS1216E were missing in Group 3, and ermA1 gene and two hypothetical proteins were missing in Group 4. The common feature of genetic environment of optrA from Group 1 to Group 4 was flanked by IS1216E, and all of them carried phenicol resistance gene fexA and erythromycin resistance gene ermA1 (Fig. 2a.).

Fig. 2.

a Schematic presentation of the genetic environment of optrA-containing contigs mapped on plasmids in 10 enterococci isolates investigated in this study. b Schematic presentation of optrA-containing contigs mapped on chromosome in three enterococci isolates. Arrows indicate the positions and directions of transcription of the different genes. Genes with unknown functions are not marked. According to the gene arrangement, the 10 contigs mapped on plasmids were divided into 4 groups-group 1 (29462 [MH225419], 1202_21W014 [MH225414]), group 2 (1203_10W003 [MH225415], SZ21494 [MH225420], ZJ11066 [MH225425]), group 3 (1207_26W003 [MH225416], 19677 [MH225418], XM2013_71028 [MH225424]), group 4 (WHXH [MH225422], XM2013_42321 [MH225423])

The contigs containing optrA gene of 1202_13E004 (MH225413) (29141 bp), 19506 (MH225417) (22720 bp) and TZ2 (MH225421) (75117 bp) were mapped on chromosomal (CP008816). The strains 1202_13E004 and 19506 contained a transposon Tn558 (AJ715531) with three transposases and the resistance gene fexA, and the resistance gene optrA was adjacent to resistance gene ermA1. The strain TZ2 carried another transposon Tn554 (X03216) with three transposases and the resistance gene ermA1, and optrA was adjacent to resistance gene fexA (Fig. 2b.).

Discussion

This study indicates that the transferable resistance gene optrA is very prevalent among linezolid-resistant enterococci strains isolated from human. Much more optrA gene is located on plasmid than chromosome. The optrA gene located on plasmid is flanked by IS1216E, while that located on chromosome is mediated by transposons.

In this study, none of linezolid-resistant enterococci strains carried cfr, while most of them harbored optrA. This suggests that acquiring optrA is the main resistant mechanism in linezolid-resistant enterococci from human origin. The presence of optrA was limited to a few species of the genus Enterococcus [35] and only rare species of Staphylococcus [4]. The surveillance studies indicated that only 3.9–6.2% of staphylococci strains were positive for optrA [4, 25], which suggests a low prevalence of this oxazolidinone resistance gene in the genus Staphylococcus.

In present study, the optrA gene was located on plasmids in most of enterococci strains. The optrA gene is often surrounded by insertion sequences when located on plasmids from enterococci strains. Our data showed that all of optrA found on plasmids were flanked by IS1216E, which was similar to a previous study [26]. Other studies also found that co-localization of optrA and cfr was close to IS21–558 and IS257 in S. sciuri [4, 27]. IS1216E belongs to the IS6 family which among other mediates transmission of the vancomycin resistance gene vanA in E. faecium, the oxazolidinone resistance gene cfr in E. faecalis [36], the macrolide-lincosamide-streptogramin B resistance genes erm(B) and erm(T) in E. hirae [37] and Streptococcus gallolyticus subsp. pasteurianus [38], respectively, and the tetracycline resistance gene tet(S) in Streptococcus infantis [39]. This indicates that optrA can be transferred between different genus bacteria by IS-mediated recombination events. Our study found that the optrA gene was located on chromosome in a few of enterococci strains. The optrA gene was adjacent to transposon Tn558 in two strains and to Tn554 in one strain. Tn558 was also detected upstream of optrA gene in S. sciuri and E. faecalis. The functionally active Tn558 and Tn554 could excise from their host DNA and produce circular forms which precede the integration of the transposon into a new target sequence [40]. The similar genetic arrangement of Tn554 and optrA was identified in both of staphylococci and enterococci, which suggest optrA can be disseminated mediated by transposon between different genus bacteria. The optrA gene was flanked by insertion sequences or transposons, indicating that mobile genetic elements mediate horizontal transfer of optrA among different genus bacteria, which should be given more attention to avoid this novel oxazolidinone resistance gene dissemination in hospitals.

Our data showed the co-localization of resistance genes fexA (n = 13) and ermA1 (n = 9) with optrA. The gene fexA mediates resistance to fluorinated and non-fluorinated phenicols, which are widely used in livestock, but not in humans. The fexA gene was prevalent in florfenicol-resistant staphylcococci [4] and enterococci [23] from animal origin. The evidence of co-localization of fexA, ermA1 and optrA indicates that linezolid-resistant strains may be selected due to non-oxazolidinone antibiotics usage, such as macrolides (often used in hospital), florfenicol (often used in livestock) and et al.. The widespread use of florfenicol in livestock has exerted selective pressure on environmental bacteria and poses a significant public health threat to the increased resistance of the novel antibiotic linezolid.

In summary, optrA was found in most of linezolid-resistant enterococci. The high diversity of optrA-carrying genetic platforms was found even in a limited number of analyzed isolates. The role of optrA in enterococci resistance to linezolid requires further investigation. The optrA gene was often flanked by insertion sequences or transposons, which might mediate the spread of optrA between different species or strains. The co-localization of fexA, ermA1 and optrA suggests that linezolid-resistant enterococci can be selected by other antibiotics such as macrolides and so on, which should be given more attention in clinical practice.

Conclusion

We discovered the high diversity of optrA-carrying genetic platforms in our limited number of analyzed isolates. MGE mediated the dissemination of optrA between different species or strains. The optrA gene was found in most of the linezolid-resistant enterococci. Further studies should be done to clarify the linezolid resistance mechanism of optrA gene in Enterococcus species.

Abbreviations

ABC

ATP-binding cassette

cfr

chloramphenicol-florfenicol resistance

IS

Insertion sequences

MATE

Multidrug and toxic compound extrusion

MDR

Multi-drug resistant

MGE

Mobile genetic element

MICs

Minimal inhibitory concentrations

MRSA

Methicillin-resistant Staphylococcus aureus

PhLOPS_A

Phenicols, lincosamide, oxazolidinones, pleuromutilin, and streptogramin A

VRE

Vancomycin-resistant enterococci

VRSA

Vancomycin-resistant Staphylococcus aureus

WGS

Whole-genome sequencing

Authors’ contributions

HW conceived and designed the study. HC, XW, YY, SL, YZ and QW performed experiments described in this study. HC wrote the draft, and HW revised it. All authors approved the final version.

Funding

This study was supported by the National Natural Science Foundation of China (No. 81471990).

Availability of data and materials

The sequences of the optrA-containing regions of 13 enterococci strains have been deposited at GenBank under the following accession numbers MH225413 (1202_13E004), MH225414 (1202_21W014), MH225415 (1203_10W003), MH225416 (1207_26W003), MH225417 (19506), MH225418 (19677), MH225419 (29462), MH225420 (SZ21494), MH225421 (TZ2), MH225422 (WHXH), MH225423 (XM2013_42321), MH225424 (XM2013_71028) and MH225425 (ZJ11066).

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.